NewLimit said Tuesday it has raised a $435 million Series C round at a $3.1 billion post-money valuation.
NewLimit co-founder Brian Armstrong (Photographer: Stefan Wermuth/Bloomberg via Getty Images)
June 2, 2026 01:34 PM EDT
FinancingStartups
Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027
Andrew Dunn
NewLimit triples valuation to $3B with $435M funding round
Longevity startup NewLimit raises $435 million ahead of first clinical trial
Claude company Anthropic nears a trillion-dollar valuation after raising $65 billion in Series H
Anthropic raised a funding round valuing it at nearly $1 trillion.
Anthropic raises $65B Series H at $965B valuation, topping OpenAI
Anthropic valued at $965 billion after latest funding round, eclipsing OpenAI
Anthropic raises $65 Billion, nears $1T valuation ahead of IPO | TechCrunch
Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment
Anthropic vaults to a $965 billion valuation with new funding as Claude demand surges
Anthropic vale quasi mille miliardi di dollari dopo un mega-round di investimento da 65 miliardi
NewLimit, co-founded by Coinbase CEO Brian Armstrong, raises $435M at a $3.1B valuation for its epigenetic reprogramming approach…
Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million…
Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it…
Life Biosciences will test its gene therapy designed to partially reset a cell’s age and reverse vision loss in patients with…
San Diego's cAMPfield Therapeutics raises $180M Series A backed by Novo Holdings, RA Capital and seven other top-tier life…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
